Bortezomib upregulates [corrected] the osterix expression by osteoblasts in the myeloma microenvironment: Implications into osteoblast function in myeloma bone disease.
Terpos
Evangelos
E
D000970:Antineoplastic Agents / Q000494:pharmacology; D016723:Bone Remodeling / Q000187:drug effects / Q000235:genetics; D001897:Boronic Acids / Q000494:pharmacology*; D000069286:Bortezomib; D015536:Down-Regulation / Q000187:drug effects; D015972:Gene Expression Regulation, Neoplastic / Q000187:drug effects; D006801:Humans; D009101:Multiple Myeloma / Q000150:complications / Q000235:genetics / Q000378:metabolism / Q000473:pathology*; D010006:Osteoblasts / Q000187:drug effects* / Q000378:metabolism / Q000473:pathology / Q000502:physiology*; D010015:Osteolysis, Essential / Q000209:etiology* / Q000235:genetics / Q000378:metabolism; D011719:Pyrazines / Q000494:pharmacology*; D000076182:Sp7 Transcription Factor; D014157:Transcription Factors / Q000235:genetics* / Q000378:metabolism
D000970:Antineoplastic Agents; D001897:Boronic Acids; D011719:Pyrazines; D000076182:Sp7 Transcription Factor; C478163:SP7 protein, human; D014157:Transcription Factors; D000069286:Bortezomib